Spero Therapeutics Inc (NASDAQ:SPRO)

13.15
Delayed Data
As of Apr 26
 -0.26 / -1.94%
Today’s Change
9.66
Today|||52-Week Range
19.00
+11.91%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$172.4M

Company Description

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Contact Information

Spero Therapeutics, Inc.
675 Massachusetts Avenue
Cambridge Massachusetts 02139
P:(857) 242-1600
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Ankit A. MahadeviaPresident, Chief Executive Officer & Director
Cristina LarkinChief Operating Officer
Joel D. SendekCFO, Treasurer & Principal Accounting Officer
Thomas R. ParrChief Scientific Officer
David MelnickChief Medical Officer